| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 35 | 2022 | 228 | 6.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 90 | 2023 | 2605 | 6.480 |
Why?
|
| Ovarian Neoplasms | 55 | 2023 | 800 | 5.580 |
Why?
|
| Breast Neoplasms | 67 | 2023 | 3155 | 4.000 |
Why?
|
| Paclitaxel | 42 | 2023 | 488 | 2.510 |
Why?
|
| Neoplasm Recurrence, Local | 41 | 2023 | 1463 | 2.350 |
Why?
|
| Tamoxifen | 19 | 2022 | 171 | 2.330 |
Why?
|
| Neoplasms, Glandular and Epithelial | 10 | 2017 | 78 | 2.300 |
Why?
|
| Antineoplastic Agents | 34 | 2023 | 2385 | 2.240 |
Why?
|
| Chemotherapy, Adjuvant | 34 | 2023 | 517 | 1.970 |
Why?
|
| Genital Neoplasms, Female | 8 | 2023 | 114 | 1.870 |
Why?
|
| Uterine Cervical Neoplasms | 9 | 2023 | 318 | 1.810 |
Why?
|
| Female | 201 | 2023 | 49872 | 1.690 |
Why?
|
| Sirolimus | 9 | 2018 | 177 | 1.620 |
Why?
|
| Androstadienes | 12 | 2022 | 74 | 1.380 |
Why?
|
| Antineoplastic Agents, Hormonal | 17 | 2022 | 154 | 1.350 |
Why?
|
| Aromatase Inhibitors | 9 | 2018 | 32 | 1.310 |
Why?
|
| Receptor, ErbB-2 | 15 | 2023 | 280 | 1.260 |
Why?
|
| Humans | 214 | 2023 | 95802 | 1.220 |
Why?
|
| Receptors, Glucocorticoid | 7 | 2022 | 144 | 1.220 |
Why?
|
| Ovary | 9 | 2019 | 267 | 1.200 |
Why?
|
| Aged | 119 | 2023 | 20848 | 1.180 |
Why?
|
| Fallopian Tube Neoplasms | 8 | 2019 | 39 | 1.170 |
Why?
|
| Middle Aged | 130 | 2023 | 28208 | 1.120 |
Why?
|
| Peritoneal Neoplasms | 9 | 2019 | 187 | 1.110 |
Why?
|
| Fluorouracil | 9 | 2015 | 549 | 1.080 |
Why?
|
| Carcinoma | 7 | 2014 | 444 | 1.070 |
Why?
|
| Disease-Free Survival | 35 | 2022 | 1194 | 1.040 |
Why?
|
| Aged, 80 and over | 57 | 2023 | 7215 | 1.000 |
Why?
|
| Adult | 116 | 2023 | 28578 | 0.990 |
Why?
|
| Carboplatin | 17 | 2023 | 328 | 0.970 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2019 | 315 | 0.930 |
Why?
|
| Premenopause | 16 | 2022 | 63 | 0.920 |
Why?
|
| Benzimidazoles | 7 | 2022 | 112 | 0.880 |
Why?
|
| Neoplasm Metastasis | 18 | 2020 | 1079 | 0.870 |
Why?
|
| Neoplasms | 26 | 2021 | 3242 | 0.850 |
Why?
|
| Antibodies, Monoclonal | 14 | 2022 | 1425 | 0.830 |
Why?
|
| Drug Administration Schedule | 25 | 2021 | 857 | 0.820 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2020 | 644 | 0.820 |
Why?
|
| Cisplatin | 17 | 2023 | 599 | 0.810 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2021 | 245 | 0.810 |
Why?
|
| Uterine Neoplasms | 4 | 2010 | 277 | 0.810 |
Why?
|
| Carcinosarcoma | 5 | 2020 | 29 | 0.770 |
Why?
|
| Antibodies, Monoclonal, Humanized | 20 | 2022 | 1021 | 0.770 |
Why?
|
| Quality of Life | 16 | 2020 | 1816 | 0.760 |
Why?
|
| Receptors, Estrogen | 10 | 2019 | 417 | 0.760 |
Why?
|
| Antineoplastic Agents, Phytogenic | 16 | 2008 | 270 | 0.740 |
Why?
|
| Combined Modality Therapy | 15 | 2023 | 1739 | 0.730 |
Why?
|
| Prognosis | 24 | 2023 | 3990 | 0.730 |
Why?
|
| Clinical Trials as Topic | 14 | 2020 | 1166 | 0.700 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 6 | 2021 | 87 | 0.690 |
Why?
|
| Neoplasm Staging | 26 | 2021 | 2042 | 0.660 |
Why?
|
| Cystadenocarcinoma, Serous | 7 | 2019 | 68 | 0.630 |
Why?
|
| Pyridines | 5 | 2022 | 319 | 0.620 |
Why?
|
| Megestrol Acetate | 3 | 2016 | 10 | 0.610 |
Why?
|
| Quinazolines | 8 | 2019 | 216 | 0.610 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2015 | 92 | 0.600 |
Why?
|
| Treatment Outcome | 36 | 2021 | 9167 | 0.590 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 97 | 0.590 |
Why?
|
| Leucovorin | 5 | 2015 | 215 | 0.580 |
Why?
|
| Doxorubicin | 14 | 2019 | 290 | 0.570 |
Why?
|
| Circadian Rhythm | 2 | 2015 | 299 | 0.540 |
Why?
|
| Receptors, Progesterone | 7 | 2019 | 196 | 0.530 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 322 | 0.520 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 192 | 0.500 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2020 | 1965 | 0.490 |
Why?
|
| Bevacizumab | 11 | 2022 | 275 | 0.450 |
Why?
|
| Age Factors | 5 | 2023 | 1957 | 0.440 |
Why?
|
| Mutation | 8 | 2023 | 4374 | 0.440 |
Why?
|
| Topotecan | 7 | 2019 | 46 | 0.420 |
Why?
|
| Filgrastim | 5 | 2020 | 57 | 0.420 |
Why?
|
| Biomarkers, Tumor | 9 | 2020 | 1670 | 0.420 |
Why?
|
| Vinblastine | 3 | 2004 | 85 | 0.420 |
Why?
|
| Mastectomy | 9 | 2020 | 270 | 0.420 |
Why?
|
| Infusions, Intravenous | 10 | 2019 | 420 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2019 | 933 | 0.410 |
Why?
|
| Deoxycytidine | 6 | 2021 | 216 | 0.390 |
Why?
|
| Survival Rate | 14 | 2020 | 1971 | 0.390 |
Why?
|
| Sarcoma | 3 | 2007 | 224 | 0.380 |
Why?
|
| Radiosurgery | 3 | 2021 | 316 | 0.370 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 8 | 2004 | 158 | 0.370 |
Why?
|
| Survival Analysis | 14 | 2021 | 1540 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 307 | 0.360 |
Why?
|
| Immunohistochemistry | 10 | 2022 | 1827 | 0.360 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 2 | 2021 | 12 | 0.360 |
Why?
|
| Young Adult | 20 | 2023 | 7026 | 0.360 |
Why?
|
| Leiomyosarcoma | 2 | 2011 | 48 | 0.350 |
Why?
|
| Anilides | 2 | 2022 | 46 | 0.330 |
Why?
|
| Medical Oncology | 4 | 2016 | 408 | 0.330 |
Why?
|
| Benzenesulfonates | 2 | 2011 | 50 | 0.330 |
Why?
|
| B7-H1 Antigen | 3 | 2022 | 306 | 0.330 |
Why?
|
| Triptorelin Pamoate | 5 | 2019 | 8 | 0.330 |
Why?
|
| Phthalazines | 4 | 2022 | 53 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 611 | 0.320 |
Why?
|
| Survivors | 2 | 2008 | 204 | 0.300 |
Why?
|
| Lymphedema | 2 | 2020 | 84 | 0.300 |
Why?
|
| Ki-67 Antigen | 2 | 2022 | 67 | 0.300 |
Why?
|
| Follow-Up Studies | 16 | 2022 | 3904 | 0.300 |
Why?
|
| Pyrroles | 4 | 2020 | 172 | 0.290 |
Why?
|
| Taxoids | 5 | 2022 | 129 | 0.290 |
Why?
|
| Women's Health | 2 | 2007 | 109 | 0.290 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2015 | 299 | 0.290 |
Why?
|
| Administration, Oral | 12 | 2019 | 686 | 0.290 |
Why?
|
| Pyrazoles | 3 | 2022 | 161 | 0.290 |
Why?
|
| Self Report | 4 | 2020 | 328 | 0.280 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2017 | 61 | 0.280 |
Why?
|
| Nervous System Diseases | 2 | 2007 | 172 | 0.280 |
Why?
|
| Enzyme Inhibitors | 5 | 2021 | 655 | 0.270 |
Why?
|
| Chemoradiotherapy | 2 | 2020 | 327 | 0.270 |
Why?
|
| Maximum Tolerated Dose | 6 | 2018 | 270 | 0.270 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2012 | 113 | 0.260 |
Why?
|
| Etoposide | 4 | 2007 | 207 | 0.250 |
Why?
|
| Piperidines | 2 | 2019 | 171 | 0.250 |
Why?
|
| Platinum | 1 | 2007 | 67 | 0.250 |
Why?
|
| Complementary Therapies | 1 | 2007 | 55 | 0.250 |
Why?
|
| Piperazines | 3 | 2019 | 296 | 0.250 |
Why?
|
| Kidney Diseases | 3 | 2003 | 323 | 0.240 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 211 | 0.240 |
Why?
|
| Neutropenia | 9 | 2018 | 211 | 0.240 |
Why?
|
| Proportional Hazards Models | 8 | 2021 | 900 | 0.240 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2018 | 217 | 0.240 |
Why?
|
| Ribose | 2 | 2022 | 20 | 0.240 |
Why?
|
| Metformin | 2 | 2018 | 125 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2019 | 883 | 0.230 |
Why?
|
| Indoles | 4 | 2015 | 317 | 0.230 |
Why?
|
| Albumins | 4 | 2023 | 135 | 0.220 |
Why?
|
| Cyclophosphamide | 5 | 2015 | 292 | 0.220 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2015 | 18 | 0.220 |
Why?
|
| Platinum Compounds | 3 | 2019 | 29 | 0.220 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 404 | 0.220 |
Why?
|
| Liver Diseases | 2 | 2003 | 249 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 449 | 0.210 |
Why?
|
| Male | 38 | 2021 | 45686 | 0.210 |
Why?
|
| Rosaniline Dyes | 1 | 2023 | 9 | 0.210 |
Why?
|
| Pelvic Neoplasms | 1 | 2004 | 44 | 0.210 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 103 | 0.200 |
Why?
|
| Adenocarcinoma | 4 | 2015 | 1192 | 0.200 |
Why?
|
| Niacinamide | 3 | 2014 | 102 | 0.200 |
Why?
|
| Prospective Studies | 7 | 2020 | 4664 | 0.200 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2003 | 6 | 0.200 |
Why?
|
| Phenylurea Compounds | 3 | 2014 | 99 | 0.200 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 61 | 0.200 |
Why?
|
| Recombinant Proteins | 7 | 2004 | 1006 | 0.190 |
Why?
|
| Lymphatic Metastasis | 6 | 2016 | 506 | 0.190 |
Why?
|
| Disease Progression | 5 | 2019 | 1559 | 0.190 |
Why?
|
| Cohort Studies | 7 | 2023 | 3106 | 0.190 |
Why?
|
| Epigenesis, Genetic | 3 | 2023 | 555 | 0.180 |
Why?
|
| Estrogens | 2 | 2016 | 202 | 0.180 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 10 | 0.180 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2021 | 17 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 224 | 0.180 |
Why?
|
| Capecitabine | 2 | 2020 | 99 | 0.180 |
Why?
|
| Safety | 3 | 2020 | 147 | 0.180 |
Why?
|
| Aminopyridines | 1 | 2022 | 49 | 0.180 |
Why?
|
| Genes, BRCA2 | 5 | 2021 | 162 | 0.180 |
Why?
|
| Genes, BRCA1 | 5 | 2021 | 192 | 0.170 |
Why?
|
| Oxidoreductases | 3 | 2003 | 115 | 0.170 |
Why?
|
| Triazoles | 3 | 2009 | 110 | 0.170 |
Why?
|
| Azacitidine | 2 | 2019 | 149 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2021 | 44 | 0.170 |
Why?
|
| Time Factors | 11 | 2019 | 5561 | 0.160 |
Why?
|
| Polyethylene Glycols | 3 | 2019 | 376 | 0.160 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 19 | 0.160 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 22 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 284 | 0.160 |
Why?
|
| Trastuzumab | 4 | 2009 | 88 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2020 | 71 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2019 | 178 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 45 | 0.160 |
Why?
|
| Maintenance Chemotherapy | 4 | 2021 | 91 | 0.160 |
Why?
|
| Body Weight | 1 | 2021 | 460 | 0.150 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 76 | 0.150 |
Why?
|
| Surveys and Questionnaires | 2 | 2007 | 2859 | 0.150 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2014 | 62 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2020 | 131 | 0.150 |
Why?
|
| Double-Blind Method | 7 | 2021 | 1791 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 70 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 1346 | 0.150 |
Why?
|
| Radiation Oncology | 3 | 2016 | 124 | 0.150 |
Why?
|
| Myasthenia Gravis | 1 | 2019 | 83 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2020 | 226 | 0.150 |
Why?
|
| Indazoles | 1 | 2019 | 61 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 128 | 0.140 |
Why?
|
| Vaginal Neoplasms | 1 | 1999 | 84 | 0.140 |
Why?
|
| Recurrence | 4 | 2018 | 1211 | 0.140 |
Why?
|
| Steroids | 1 | 2019 | 173 | 0.140 |
Why?
|
| Ketoconazole | 3 | 2012 | 24 | 0.140 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2017 | 59 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2018 | 63 | 0.140 |
Why?
|
| Thrombocytopenia | 5 | 2018 | 187 | 0.140 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 16 | 0.140 |
Why?
|
| Retreatment | 1 | 2018 | 106 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 209 | 0.140 |
Why?
|
| United States | 10 | 2021 | 7764 | 0.140 |
Why?
|
| Mifepristone | 2 | 2015 | 51 | 0.130 |
Why?
|
| Stathmin | 1 | 2017 | 3 | 0.130 |
Why?
|
| Body Mass Index | 4 | 2021 | 815 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 81 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2018 | 120 | 0.130 |
Why?
|
| California | 5 | 2020 | 161 | 0.130 |
Why?
|
| Camptothecin | 4 | 2003 | 202 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2018 | 238 | 0.130 |
Why?
|
| Disease Management | 1 | 2019 | 360 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 320 | 0.130 |
Why?
|
| Incidence | 4 | 2020 | 1714 | 0.130 |
Why?
|
| Health Services Misuse | 1 | 2016 | 21 | 0.130 |
Why?
|
| Germ-Line Mutation | 4 | 2021 | 382 | 0.120 |
Why?
|
| Estradiol | 3 | 2016 | 255 | 0.120 |
Why?
|
| Research Design | 3 | 2021 | 630 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 135 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 725 | 0.120 |
Why?
|
| Benzamides | 1 | 2017 | 248 | 0.120 |
Why?
|
| Nitriles | 2 | 2009 | 157 | 0.120 |
Why?
|
| Chromatin | 1 | 2019 | 444 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 357 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 114 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 354 | 0.120 |
Why?
|
| Fatigue | 4 | 2019 | 185 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 76 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2018 | 417 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 3 | 2022 | 174 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 1997 | 240 | 0.120 |
Why?
|
| Induction Chemotherapy | 3 | 2021 | 151 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 431 | 0.120 |
Why?
|
| Amines | 1 | 2015 | 31 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2020 | 454 | 0.120 |
Why?
|
| Transcriptome | 2 | 2018 | 769 | 0.110 |
Why?
|
| Nanomedicine | 1 | 2015 | 16 | 0.110 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 3 | 2021 | 60 | 0.110 |
Why?
|
| Ascites | 1 | 2015 | 57 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 182 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2015 | 74 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 149 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2013 | 116 | 0.110 |
Why?
|
| Neural Stem Cells | 1 | 2015 | 69 | 0.110 |
Why?
|
| Area Under Curve | 7 | 2018 | 340 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 87 | 0.110 |
Why?
|
| Antifungal Agents | 2 | 2007 | 126 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 1805 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1999 | 382 | 0.110 |
Why?
|
| Uracil | 3 | 2005 | 56 | 0.110 |
Why?
|
| Benzazepines | 1 | 2015 | 65 | 0.110 |
Why?
|
| Body Fluids | 1 | 2014 | 35 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 367 | 0.110 |
Why?
|
| Lymph Node Excision | 3 | 2020 | 234 | 0.110 |
Why?
|
| Cervix Uteri | 1 | 2014 | 73 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 155 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2015 | 134 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 301 | 0.100 |
Why?
|
| Obstetric Labor, Premature | 1 | 2014 | 58 | 0.100 |
Why?
|
| Ketones | 1 | 2013 | 14 | 0.100 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2013 | 7 | 0.100 |
Why?
|
| Furans | 1 | 2013 | 19 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2015 | 118 | 0.100 |
Why?
|
| Fibronectins | 1 | 2014 | 100 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 218 | 0.100 |
Why?
|
| Glucocorticoids | 2 | 2022 | 369 | 0.100 |
Why?
|
| Survival | 2 | 2021 | 21 | 0.100 |
Why?
|
| Research | 1 | 2015 | 265 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2022 | 365 | 0.100 |
Why?
|
| Lung Neoplasms | 4 | 2018 | 2386 | 0.100 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 23 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 21 | 0.100 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 32 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 45 | 0.100 |
Why?
|
| Pyrimidines | 2 | 2012 | 386 | 0.100 |
Why?
|
| Chordoma | 1 | 1993 | 42 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 376 | 0.100 |
Why?
|
| Vagina | 1 | 2014 | 181 | 0.100 |
Why?
|
| Folic Acid Antagonists | 1 | 1992 | 17 | 0.100 |
Why?
|
| Risk Factors | 7 | 2019 | 5961 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2008 | 238 | 0.100 |
Why?
|
| Sacrum | 1 | 1993 | 84 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 460 | 0.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2003 | 37 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 153 | 0.090 |
Why?
|
| CA-125 Antigen | 2 | 2022 | 21 | 0.090 |
Why?
|
| Models, Neurological | 1 | 2015 | 435 | 0.090 |
Why?
|
| Megestrol | 1 | 1992 | 4 | 0.090 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 3 | 2003 | 28 | 0.090 |
Why?
|
| Gene Amplification | 2 | 2009 | 142 | 0.090 |
Why?
|
| Interferon-alpha | 3 | 1997 | 194 | 0.090 |
Why?
|
| Peptides | 1 | 2015 | 671 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 528 | 0.090 |
Why?
|
| Vomiting | 3 | 1999 | 201 | 0.090 |
Why?
|
| Brachytherapy | 2 | 2004 | 127 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2014 | 350 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 829 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 2 | 2002 | 89 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1030 | 0.090 |
Why?
|
| Anemia | 3 | 2018 | 136 | 0.090 |
Why?
|
| Metoclopramide | 1 | 1991 | 16 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2013 | 337 | 0.080 |
Why?
|
| Radiotherapy Dosage | 3 | 2018 | 476 | 0.080 |
Why?
|
| Genes, erbB-2 | 2 | 2007 | 25 | 0.080 |
Why?
|
| Early Medical Intervention | 2 | 2020 | 19 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 943 | 0.080 |
Why?
|
| Lymph Nodes | 3 | 2017 | 554 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2022 | 936 | 0.080 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 92 | 0.080 |
Why?
|
| Exercise Therapy | 2 | 2020 | 94 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 564 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2014 | 926 | 0.080 |
Why?
|
| Canada | 2 | 2021 | 214 | 0.080 |
Why?
|
| Antiemetics | 1 | 1991 | 103 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 1992 | 453 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1096 | 0.080 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2592 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2015 | 766 | 0.070 |
Why?
|
| Diarrhea | 3 | 2019 | 181 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 1798 | 0.070 |
Why?
|
| Hysterectomy | 3 | 2019 | 168 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 1996 | 771 | 0.070 |
Why?
|
| Feasibility Studies | 4 | 2013 | 816 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2019 | 2480 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 85 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2020 | 86 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 640 | 0.070 |
Why?
|
| Anxiety | 2 | 2008 | 339 | 0.070 |
Why?
|
| Drug Interactions | 4 | 2011 | 245 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2882 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2009 | 164 | 0.070 |
Why?
|
| BRCA2 Protein | 2 | 2019 | 175 | 0.070 |
Why?
|
| Aging | 2 | 2003 | 766 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 1535 | 0.070 |
Why?
|
| Decision Making | 2 | 2016 | 694 | 0.070 |
Why?
|
| Chicago | 4 | 2015 | 1505 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 166 | 0.070 |
Why?
|
| BRCA1 Protein | 2 | 2019 | 216 | 0.070 |
Why?
|
| Tegafur | 2 | 2005 | 17 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 2777 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 198 | 0.070 |
Why?
|
| Bilirubin | 2 | 2007 | 134 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2018 | 192 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 514 | 0.060 |
Why?
|
| Animals | 8 | 2019 | 28889 | 0.060 |
Why?
|
| Glucuronosyltransferase | 2 | 2013 | 186 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2018 | 317 | 0.060 |
Why?
|
| Neurons | 1 | 2015 | 1653 | 0.060 |
Why?
|
| Ovariectomy | 2 | 2019 | 91 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2008 | 246 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 2494 | 0.060 |
Why?
|
| Surgical Oncology | 2 | 2016 | 29 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2534 | 0.060 |
Why?
|
| Nausea | 3 | 2018 | 181 | 0.060 |
Why?
|
| Stroke | 1 | 2015 | 1087 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 1267 | 0.060 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2018 | 46 | 0.060 |
Why?
|
| Patient Selection | 3 | 2008 | 708 | 0.060 |
Why?
|
| Treatment Failure | 3 | 2008 | 297 | 0.060 |
Why?
|
| Killer Cells, Natural | 2 | 2008 | 292 | 0.060 |
Why?
|
| Creatinine | 2 | 2003 | 299 | 0.060 |
Why?
|
| Psychometrics | 1 | 2007 | 340 | 0.060 |
Why?
|
| Abdomen | 1 | 2005 | 124 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 380 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2018 | 10273 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2008 | 513 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2006 | 281 | 0.060 |
Why?
|
| Comorbidity | 3 | 2021 | 1011 | 0.050 |
Why?
|
| Ontario | 2 | 2015 | 56 | 0.050 |
Why?
|
| Logistic Models | 4 | 2014 | 1267 | 0.050 |
Why?
|
| Infusions, Parenteral | 2 | 2019 | 51 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 456 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2007 | 347 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 312 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2023 | 102 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2002 | 18 | 0.050 |
Why?
|
| Chromium | 1 | 2002 | 17 | 0.050 |
Why?
|
| Depression | 1 | 2007 | 560 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 18 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2008 | 599 | 0.050 |
Why?
|
| Pentostatin | 1 | 2002 | 13 | 0.050 |
Why?
|
| Bridged-Ring Compounds | 1 | 2022 | 16 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2016 | 644 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 297 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 63 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2022 | 73 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1957 | 0.050 |
Why?
|
| Food-Drug Interactions | 1 | 2002 | 19 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2021 | 22 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 174 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2021 | 85 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 196 | 0.040 |
Why?
|
| Epigenomics | 1 | 2022 | 109 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 547 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 15 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2021 | 88 | 0.040 |
Why?
|
| Adolescent | 4 | 2019 | 9873 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 50 | 0.040 |
Why?
|
| Thionucleotides | 1 | 2001 | 56 | 0.040 |
Why?
|
| Breast | 1 | 2023 | 297 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2003 | 325 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 26 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2001 | 37 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2001 | 52 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 478 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2001 | 41 | 0.040 |
Why?
|
| Patient Participation | 1 | 2003 | 241 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2002 | 239 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 1087 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2002 | 726 | 0.040 |
Why?
|
| Methotrexate | 1 | 2001 | 232 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 465 | 0.040 |
Why?
|
| Dipeptidases | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Axilla | 2 | 2016 | 110 | 0.040 |
Why?
|
| Remission Induction | 2 | 2006 | 750 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 34 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Thalidomide | 1 | 2000 | 56 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 30 | 0.040 |
Why?
|
| Arm | 1 | 2020 | 100 | 0.040 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 33 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 983 | 0.040 |
Why?
|
| Biomarkers | 3 | 2014 | 1931 | 0.040 |
Why?
|
| Leukopenia | 2 | 1997 | 65 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2020 | 180 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2008 | 403 | 0.040 |
Why?
|
| Capsules | 2 | 2013 | 38 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 565 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 81 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 557 | 0.040 |
Why?
|
| Hand | 1 | 2020 | 168 | 0.040 |
Why?
|
| Mice | 3 | 2019 | 12537 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 207 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 22 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2001 | 415 | 0.040 |
Why?
|
| Genotype | 2 | 2020 | 1880 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 1046 | 0.040 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2004 | 68 | 0.040 |
Why?
|
| Hydroxyurea | 1 | 1999 | 235 | 0.040 |
Why?
|
| Drug Evaluation | 2 | 2001 | 127 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 213 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 31 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2014 | 99 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2008 | 90 | 0.030 |
Why?
|
| Gallbladder Neoplasms | 1 | 2018 | 23 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 579 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 188 | 0.030 |
Why?
|
| Heart | 1 | 2001 | 590 | 0.030 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 63 | 0.030 |
Why?
|
| Kidney Pelvis | 1 | 2018 | 52 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2018 | 120 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2019 | 516 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 223 | 0.030 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 80 | 0.030 |
Why?
|
| Isotretinoin | 1 | 1997 | 20 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 91 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 897 | 0.030 |
Why?
|
| Antidotes | 1 | 1997 | 24 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 308 | 0.030 |
Why?
|
| Injections | 1 | 1997 | 126 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2018 | 228 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 157 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 134 | 0.030 |
Why?
|
| Rats | 1 | 2003 | 4154 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2020 | 447 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2009 | 2089 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2019 | 3581 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2008 | 42 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 80 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 156 | 0.030 |
Why?
|
| Tretinoin | 1 | 1997 | 131 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 562 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 1996 | 66 | 0.030 |
Why?
|
| Estrone | 1 | 2016 | 10 | 0.030 |
Why?
|
| Fever | 1 | 1997 | 131 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 404 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2016 | 146 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 2016 | 168 | 0.030 |
Why?
|
| Snake Venoms | 1 | 2015 | 9 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 1029 | 0.030 |
Why?
|
| HIV-1 | 1 | 1997 | 182 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1156 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 985 | 0.030 |
Why?
|
| Postmenopause | 2 | 2009 | 107 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1560 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1730 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 277 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 120 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 491 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 787 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 321 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 996 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 146 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 1145 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 279 | 0.030 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2014 | 7 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2018 | 333 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2015 | 99 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 1192 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2014 | 30 | 0.030 |
Why?
|
| Perception | 2 | 2008 | 185 | 0.030 |
Why?
|
| Cyclohexenes | 1 | 1994 | 5 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 1008 | 0.030 |
Why?
|
| Cell Death | 1 | 2015 | 264 | 0.030 |
Why?
|
| Benzofurans | 1 | 1994 | 9 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 322 | 0.030 |
Why?
|
| Australia | 1 | 2014 | 124 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 220 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2015 | 136 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1208 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 296 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2013 | 50 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 1994 | 78 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 426 | 0.030 |
Why?
|
| Arylsulfotransferase | 1 | 2013 | 4 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 236 | 0.030 |
Why?
|
| Sulfotransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 1999 | 1981 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 173 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1753 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 72 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 318 | 0.020 |
Why?
|
| Hypertension | 1 | 2019 | 774 | 0.020 |
Why?
|
| Trimetrexate | 1 | 1992 | 4 | 0.020 |
Why?
|
| Aminopterin | 1 | 1992 | 5 | 0.020 |
Why?
|
| Tetrahydrofolates | 1 | 1992 | 13 | 0.020 |
Why?
|
| Nigeria | 1 | 2013 | 162 | 0.020 |
Why?
|
| Eligibility Determination | 2 | 2003 | 38 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2014 | 131 | 0.020 |
Why?
|
| Citrus paradisi | 1 | 2012 | 5 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2013 | 236 | 0.020 |
Why?
|
| Thiophenes | 1 | 1992 | 45 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2013 | 212 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 621 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 170 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2012 | 31 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 155 | 0.020 |
Why?
|
| Pelvis | 2 | 2003 | 103 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 701 | 0.020 |
Why?
|
| Vindesine | 1 | 1992 | 5 | 0.020 |
Why?
|
| Affinity Labels | 1 | 1992 | 9 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 169 | 0.020 |
Why?
|
| Azides | 1 | 1992 | 12 | 0.020 |
Why?
|
| Chemistry, Physical | 1 | 1992 | 29 | 0.020 |
Why?
|
| Dihydropyridines | 1 | 1992 | 7 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 91 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1992 | 72 | 0.020 |
Why?
|
| Tritium | 1 | 1992 | 132 | 0.020 |
Why?
|
| Vincristine | 1 | 1992 | 101 | 0.020 |
Why?
|
| Drug Combinations | 2 | 2005 | 213 | 0.020 |
Why?
|
| Cricetulus | 1 | 1992 | 132 | 0.020 |
Why?
|
| Tablets | 1 | 2013 | 127 | 0.020 |
Why?
|
| Forecasting | 1 | 1992 | 317 | 0.020 |
Why?
|
| Progesterone | 1 | 1992 | 112 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 790 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1992 | 138 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 635 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2012 | 181 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1992 | 234 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 1087 | 0.020 |
Why?
|
| Cricetinae | 1 | 1992 | 542 | 0.020 |
Why?
|
| Epithelium | 1 | 1992 | 322 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1991 | 61 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1993 | 316 | 0.020 |
Why?
|
| Nasopharyngeal Diseases | 1 | 1990 | 1 | 0.020 |
Why?
|
| Otitis Media, Suppurative | 1 | 1990 | 4 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 484 | 0.020 |
Why?
|
| Otitis Media | 1 | 1990 | 20 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2002 | 204 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2473 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2039 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1990 | 94 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 50 | 0.020 |
Why?
|
| Climacteric | 1 | 2008 | 4 | 0.020 |
Why?
|
| Chemokine CXCL9 | 1 | 2008 | 8 | 0.020 |
Why?
|
| Sick Role | 1 | 2008 | 13 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2008 | 23 | 0.020 |
Why?
|
| Placebos | 1 | 2009 | 213 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2008 | 147 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 147 | 0.020 |
Why?
|
| Goserelin | 1 | 2008 | 5 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2009 | 108 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 204 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 20 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1992 | 400 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2008 | 22 | 0.020 |
Why?
|
| E-Selectin | 1 | 2008 | 31 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 87 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 161 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 78 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 1992 | 705 | 0.020 |
Why?
|
| Exanthema | 1 | 2008 | 41 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 796 | 0.020 |
Why?
|
| Life Style | 1 | 2008 | 186 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 142 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 353 | 0.020 |
Why?
|
| Health Behavior | 1 | 2008 | 191 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 366 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 381 | 0.020 |
Why?
|
| Pregnancy | 1 | 2014 | 3237 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2008 | 462 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1992 | 2929 | 0.020 |
Why?
|
| Social Support | 1 | 2008 | 239 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 1422 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 930 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 150 | 0.020 |
Why?
|
| Microspheres | 1 | 2006 | 105 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2006 | 117 | 0.010 |
Why?
|
| Radiodermatitis | 1 | 2005 | 10 | 0.010 |
Why?
|
| Lung | 1 | 1992 | 1380 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 378 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2004 | 9 | 0.010 |
Why?
|
| Communication | 1 | 2008 | 478 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2007 | 687 | 0.010 |
Why?
|
| Models, Biological | 2 | 2002 | 1809 | 0.010 |
Why?
|
| Cyclins | 1 | 2004 | 80 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 79 | 0.010 |
Why?
|
| Mammaplasty | 1 | 2005 | 124 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 1756 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 378 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 362 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 1069 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 119 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2002 | 16 | 0.010 |
Why?
|
| Glucuronides | 1 | 2002 | 34 | 0.010 |
Why?
|
| Population | 1 | 2002 | 37 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 2002 | 126 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 99 | 0.010 |
Why?
|
| Leukapheresis | 1 | 2001 | 16 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 397 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2001 | 86 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2001 | 90 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 217 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2001 | 163 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 55 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2000 | 30 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 55 | 0.010 |
Why?
|
| Lymphokines | 1 | 2000 | 75 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2000 | 60 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 79 | 0.010 |
Why?
|
| Lactones | 1 | 2000 | 27 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 823 | 0.010 |
Why?
|
| Macrolides | 1 | 2000 | 31 | 0.010 |
Why?
|
| Stem Cells | 1 | 2001 | 394 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1157 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 500 | 0.010 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1997 | 7 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1997 | 18 | 0.010 |
Why?
|
| South Africa | 1 | 1997 | 60 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 712 | 0.010 |
Why?
|
| Linear Models | 1 | 1996 | 438 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1996 | 908 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1990 | 2773 | 0.000 |
Why?
|